The UK's drug regulator granted approval for Kisunla, an Alzheimer's medication, while an independent assessment body rejected its NHS funding on grounds of cost. The approval marks the second ...

Donanemab has been hailed as 'game changer' but the price tag has barred it from being available to nearly one million Brits.

Eli Lilly's donanemab receives UK approval for mild cognitive impairment and mild dementia due to Alzheimer's disease.

Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...

Eli Lilly’s Alzheimer’s disease offering Kinsunla is poised to face a tough road ahead in the U.K. | Lilly's Alzheimer ...

A wife whose husband will not be eligible for new Alzheimer’s drugs has implored health leaders to ensure that others like ...

The UK’s healthcare spending watchdog has rejected Eli Lilly’s (LLY) Alzheimer’s drug as being too expensive despite being ...

A second groundbreaking drug (donanemab) for Alzheimer's disease has been rejected for widespread use by the NHS in England ...

England's drug-cost regulator rejcted Eli Lilly's Alzheimer's drug for use in the country's public health system, marking the second time a treatment for the disease has been deemed too costly.

The most effective drug for Alzheimer’s has been blocked for use on the NHS. Regulators have declared the new treatment for ...

The U.K. watchdog declines to endorse Eli Lilly's Alzheimer's drug donanemab, citing lack of value for the NHS and ...